Expected to be launched in Q1 FY 2017
Biocon announced that the Ministry of Health, Labour and Welfare of Japan has approved it biosimilar Insulin Glargine, The product is a ready to use, prefilled disposable pen with 3ml of 100IU Insulin Glargine, expected to be launched in Q1 FY 2017 with commercial partner, FUJIFILM Pharma Co. in Japan. The Company is developing Insuline Glargine for the developed markets outside Japan in collaboration with Mylan.Powered by Capital Market - Live News
